Literature DB >> 6362854

Inhibition of human melanoma cell growth in vitro by monoclonal anti-GD3-ganglioside antibody.

W G Dippold, A Knuth, K H Meyer zum Büschenfelde.   

Abstract

Malignant melanoma cell growth in vitro was blocked by the monoclonal antibody R-24, which detects the disialoganglioside GD3 on melanoma cells. GD3 expression varies greatly in cultured human malignant melanoma cells. The level of ganglioside GD3 was measured by quantitative absorption tests. In our observations, six melanoma cell lines expressing high levels of GD3 on the cell surface showed growth inhibition and rounding up in the presence of R-24 antibody. Four melanoma cell lines with low levels of GD3 and seven nonmelanoma cell lines with no detectable GD3 remained unchanged in morphology and continued to grow. The data presented indicate that complement is not involved in the growth inhibition observed here. Because ganglioside GD3 was detected in all 16 tissue specimens of primary and metastatic human malignant melanoma examined by immunofluorescence tests, the possible relevance of this finding in vivo is discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6362854

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

1.  Controlling tumor-derived and vascular endothelial cell growth: role of the 4Ff2 cell surface antigen.

Authors:  M Papetti; I M Herman
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

2.  Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin.

Authors:  C J Honsik; G Jung; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

3.  Ganglioside GD3 shedding by human gliomas.

Authors:  O Nakamura; M Iwamori; M Matsutani; K Takakura
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

4.  Ganglioside GD3 promotes cell growth and invasion through p130Cas and paxillin in malignant melanoma cells.

Authors:  Kazunori Hamamura; Keiko Furukawa; Takanori Hayashi; Takeshi Hattori; Junji Nakano; Hideyuki Nakashima; Tetsuya Okuda; Hideki Mizutani; Hisashi Hattori; Minoru Ueda; Takeshi Urano; Kenneth O Lloyd; Koichi Furukawa
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-22       Impact factor: 11.205

5.  Modulation of melanoma-associated antigens by monoclonal antibodies as visualized by radioimmunoelectron microscopy and radioantibody binding assay.

Authors:  W Tilgen; S Matzku; I Kaufmann; M Engstner; J Brüggen; W Dippold; D Petzoldt
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

6.  Monoclonal antibody against a lactose epitope of glycosphingolipids binds to melanoma tumour cells.

Authors:  K Ding; T Ekberg; J Zeuthen; S Teneberg; K A Karlsson; A Rosén
Journal:  Glycoconj J       Date:  1993-10       Impact factor: 2.916

7.  Immune response of chimpanzee to purified melanoma 250 kilodalton tumor-associated antigen.

Authors:  G M Stuhlmiller; T L Darrow; D M Haupt; H F Seigler
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

Review 8.  Ganglioside GD3: structure, cellular distribution, and possible function.

Authors:  T N Seyfried; R K Yu
Journal:  Mol Cell Biochem       Date:  1985-09       Impact factor: 3.396

9.  Gangliosides as bimodal regulators of cell growth.

Authors:  S Spiegel; P H Fishman
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

10.  Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis.

Authors:  D A Cheresh; C J Honsik; L K Staffileno; G Jung; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.